Agomab Therapeutics NV

AGMB Nasdaq CIK: 0002020932

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type other
State of Incorporation Belgium
Country Belgium
Business Address POSTHOFLEI 1/6, ANTWERPEN, , 2600
Mailing Address POSTHOFLEI 1/6, ANTWERPEN, , 2600
Phone 32 3 302 35 30
Fiscal Year End 1231
EIN 000000000

Recent SEC Filings

Form Type Date Filed Document
3 Initial insider ownership report March 18, 2026 View on SEC
3 Initial insider ownership report March 18, 2026 View on SEC
3 Initial insider ownership report March 18, 2026 View on SEC
3 Initial insider ownership report March 18, 2026 View on SEC
3 Initial insider ownership report March 18, 2026 View on SEC
3 Initial insider ownership report March 18, 2026 View on SEC
3 Initial insider ownership report March 18, 2026 View on SEC
3 Initial insider ownership report March 18, 2026 View on SEC
3 Initial insider ownership report March 18, 2026 View on SEC
3 Initial insider ownership report March 18, 2026 View on SEC

IPO Filings

F-1 January 16, 2026
  • Clear therapeutic focus, lead drug candidate, and pipeline assets.
  • Notable development milestone achieved.
View Analysis

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.